| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 75.21▼ | 75.05▼ | 75.15▼ | 80.60▼ | 82.20▼ |
| MA10 | 75.15▼ | 74.86▲ | 74.46▲ | 84.67▼ | 71.40▲ |
| MA20 | 75.14▼ | 74.47▲ | 76.45▼ | 84.38▼ | 51.16▲ |
| MA50 | 74.93▲ | 78.55▼ | 82.98▼ | 68.33▲ | 33.07▲ |
| MA100 | 74.39▲ | 83.40▼ | 86.73▼ | 48.96▲ | 34.77▲ |
| MA200 | 76.08▼ | 86.47▼ | 78.58▼ | 35.01▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.021▼ | 0.447▲ | 0.365▲ | -2.777▼ | 3.640▲ |
| RSI | 47.076▼ | 43.940▼ | 37.179▼ | 44.648▼ | 68.174▲ |
| STOCH | 61.947 | 72.205 | 62.525 | 20.274 | 75.040 |
| WILL %R | -82.778▼ | -25.585 | -61.515 | -87.561▼ | -31.238 |
| CCI | -70.971 | 74.635 | 56.349 | -186.496▼ | 67.552 |
|
Thursday, February 05, 2026 09:53 AM
Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials.
|
|
Friday, January 23, 2026 05:18 AM
Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape obesity treatment.
|
|
Friday, January 23, 2026 05:18 AM
Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape obesity treatment.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 06/02/26 | 75.50 | 76.13 | 72.27 | 74.92 | 1,101,916 |
| 05/02/26 | 79.31 | 79.39 | 72.10 | 73.21 | 2,156,295 |
| 04/02/26 | 83.97 | 84.80 | 78.99 | 81.26 | 1,011,439 |
| 03/02/26 | 88.97 | 89.94 | 82.27 | 83.78 | 1,440,628 |
| 02/02/26 | 87.58 | 92.06 | 87.55 | 89.84 | 848,149 |
| 30/01/26 | 87.15 | 90.24 | 86.665 | 88.45 | 789,915 |
| 29/01/26 | 88.48 | 89.39 | 86.10 | 87.15 | 742,027 |
| 28/01/26 | 89.01 | 90.00 | 87.345 | 89.05 | 554,298 |
| 27/01/26 | 88.89 | 91.21 | 88.02 | 89.51 | 584,419 |
| 26/01/26 | 89.60 | 91.21 | 87.00 | 89.57 | 479,372 |
|
|
||||
|
|
||||
|
|